Clinical pharmacokinetics of а new original dipeptide anxiolytic GB-115
Pharmacokinetic study of а new original anxiolytic drug GB-115, developed on the basis of endogenous tetrapeptide cholecystokinin, in healthy volunteers was performed. Volunteers were received drug as single 1, 3, 7, 11 or 15 mg tablets. The parent drug in the human blood plasma was detected within...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC “Publisher OKI”
2017-02-01
|
| Series: | Фармакокинетика и Фармакодинамика |
| Subjects: | |
| Online Access: | https://www.pharmacokinetica.ru/jour/article/view/8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849248684572672000 |
|---|---|
| author | V. P. Zherdev G. B. Kolyvanov A. A. Litvin V. V. Smirnov L. G. Kolik S. Yu. Raskin N. Yu. Ivashkina T. A. Gudasheva S. B. Seredenin |
| author_facet | V. P. Zherdev G. B. Kolyvanov A. A. Litvin V. V. Smirnov L. G. Kolik S. Yu. Raskin N. Yu. Ivashkina T. A. Gudasheva S. B. Seredenin |
| author_sort | V. P. Zherdev |
| collection | DOAJ |
| description | Pharmacokinetic study of а new original anxiolytic drug GB-115, developed on the basis of endogenous tetrapeptide cholecystokinin, in healthy volunteers was performed. Volunteers were received drug as single 1, 3, 7, 11 or 15 mg tablets. The parent drug in the human blood plasma was detected within 2-6 hours after ingestion. Cmax/AUC0-T for doses 3-15 mg were averaged 0,482-0,552 h-1. Cmax were averaged from 7,29±2,83 ng/ml (for dose 1 mg) to 44,02±13,23 ng/ml (for dose 15 mg). Half-life of the drug is changed in the range of 0,6-1,0 h. Vd/F amounted to an average of 2,47 l/kg. Summarizing the obtained results it can be concluded that consistent, linear increase in the dose of GB-115 from 1 to 15 mg there is an increase in dose-dependent pharmacokinetic parameters. In the studied range of doses pharmacokinetics of GB-115 was linear. |
| format | Article |
| id | doaj-art-0f5cfb960ca84a2f9d542ab9e0128e95 |
| institution | Kabale University |
| issn | 2587-7836 2686-8830 |
| language | Russian |
| publishDate | 2017-02-01 |
| publisher | LLC “Publisher OKI” |
| record_format | Article |
| series | Фармакокинетика и Фармакодинамика |
| spelling | doaj-art-0f5cfb960ca84a2f9d542ab9e0128e952025-08-20T03:57:48ZrusLLC “Publisher OKI”Фармакокинетика и Фармакодинамика2587-78362686-88302017-02-010152567Clinical pharmacokinetics of а new original dipeptide anxiolytic GB-115V. P. Zherdev0G. B. Kolyvanov1A. A. Litvin2V. V. Smirnov3L. G. Kolik4S. Yu. Raskin5N. Yu. Ivashkina6T. A. Gudasheva7S. B. Seredenin8FSBI «Zakusov Institute of Pharmacology»FSBI «Zakusov Institute of Pharmacology»FSBI «Zakusov Institute of Pharmacology»I.M. Sechenov First Moscow State Medical UniversityFSBI «Zakusov Institute of Pharmacology»FSBI «Zakusov Institute of Pharmacology»«Maluna-Pharm»FSBI «Zakusov Institute of Pharmacology»FSBI «Zakusov Institute of Pharmacology»Pharmacokinetic study of а new original anxiolytic drug GB-115, developed on the basis of endogenous tetrapeptide cholecystokinin, in healthy volunteers was performed. Volunteers were received drug as single 1, 3, 7, 11 or 15 mg tablets. The parent drug in the human blood plasma was detected within 2-6 hours after ingestion. Cmax/AUC0-T for doses 3-15 mg were averaged 0,482-0,552 h-1. Cmax were averaged from 7,29±2,83 ng/ml (for dose 1 mg) to 44,02±13,23 ng/ml (for dose 15 mg). Half-life of the drug is changed in the range of 0,6-1,0 h. Vd/F amounted to an average of 2,47 l/kg. Summarizing the obtained results it can be concluded that consistent, linear increase in the dose of GB-115 from 1 to 15 mg there is an increase in dose-dependent pharmacokinetic parameters. In the studied range of doses pharmacokinetics of GB-115 was linear.https://www.pharmacokinetica.ru/jour/article/view/8таблетки гб-115высокоэффективная жидкостная хроматография-масс-спектрометрияклиническая фармакокинетикаtablets of gb-115high-performance liquid chromatography/mass-spectroscopyclinical pharmacokinetics |
| spellingShingle | V. P. Zherdev G. B. Kolyvanov A. A. Litvin V. V. Smirnov L. G. Kolik S. Yu. Raskin N. Yu. Ivashkina T. A. Gudasheva S. B. Seredenin Clinical pharmacokinetics of а new original dipeptide anxiolytic GB-115 Фармакокинетика и Фармакодинамика таблетки гб-115 высокоэффективная жидкостная хроматография-масс-спектрометрия клиническая фармакокинетика tablets of gb-115 high-performance liquid chromatography/mass-spectroscopy clinical pharmacokinetics |
| title | Clinical pharmacokinetics of а new original dipeptide anxiolytic GB-115 |
| title_full | Clinical pharmacokinetics of а new original dipeptide anxiolytic GB-115 |
| title_fullStr | Clinical pharmacokinetics of а new original dipeptide anxiolytic GB-115 |
| title_full_unstemmed | Clinical pharmacokinetics of а new original dipeptide anxiolytic GB-115 |
| title_short | Clinical pharmacokinetics of а new original dipeptide anxiolytic GB-115 |
| title_sort | clinical pharmacokinetics of а new original dipeptide anxiolytic gb 115 |
| topic | таблетки гб-115 высокоэффективная жидкостная хроматография-масс-спектрометрия клиническая фармакокинетика tablets of gb-115 high-performance liquid chromatography/mass-spectroscopy clinical pharmacokinetics |
| url | https://www.pharmacokinetica.ru/jour/article/view/8 |
| work_keys_str_mv | AT vpzherdev clinicalpharmacokineticsofaneworiginaldipeptideanxiolyticgb115 AT gbkolyvanov clinicalpharmacokineticsofaneworiginaldipeptideanxiolyticgb115 AT aalitvin clinicalpharmacokineticsofaneworiginaldipeptideanxiolyticgb115 AT vvsmirnov clinicalpharmacokineticsofaneworiginaldipeptideanxiolyticgb115 AT lgkolik clinicalpharmacokineticsofaneworiginaldipeptideanxiolyticgb115 AT syuraskin clinicalpharmacokineticsofaneworiginaldipeptideanxiolyticgb115 AT nyuivashkina clinicalpharmacokineticsofaneworiginaldipeptideanxiolyticgb115 AT tagudasheva clinicalpharmacokineticsofaneworiginaldipeptideanxiolyticgb115 AT sbseredenin clinicalpharmacokineticsofaneworiginaldipeptideanxiolyticgb115 |